247 related articles for article (PubMed ID: 33550694)
1. Viral hepatitis C pandemic: Challenges and threats to its elimination.
Krekulova L; Honzák R; Riley LW
J Viral Hepat; 2021 May; 28(5):694-698. PubMed ID: 33550694
[TBL] [Abstract][Full Text] [Related]
2. Key Role of Multidisciplinary Collaboration towards Global Elimination of HCV Infection.
Krekulova L; Oktabec Z; Riley LW
Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409839
[TBL] [Abstract][Full Text] [Related]
3. Planning the hepatitis C virus elimination in Cyprus: A modeling study.
Gountas I; Yiasemi I; Kyprianou E; Mina C; Georgiou C; Katsioloudes P; Kouroufexi A; Demetriou A; Xenofontos E; Nikolopoulos G
World J Gastroenterol; 2021 Aug; 27(31):5219-5231. PubMed ID: 34497446
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis.
Muller A; Vlahov D; Akiyama MJ; Kurth A
Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32659974
[TBL] [Abstract][Full Text] [Related]
5. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all.
Grebely J; Hajarizadeh B; Lazarus JV; Bruneau J; Treloar C;
Int J Drug Policy; 2019 Oct; 72():1-10. PubMed ID: 31345644
[TBL] [Abstract][Full Text] [Related]
6. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19.
Blach S; Blomé M; Duberg AS; Jerkeman A; Kåberg M; Klasa PE; Lagging M; Razavi-Shearer D; Razavi H; Aleman S
Liver Int; 2021 Sep; 41(9):2024-2031. PubMed ID: 34051065
[TBL] [Abstract][Full Text] [Related]
8. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada.
Godin A; Kronfli N; Cox J; Alary M; Maheu-Giroux M
Int J Drug Policy; 2021 Feb; 88():102738. PubMed ID: 32278651
[TBL] [Abstract][Full Text] [Related]
9. Experience with viral hepatitis C treatment among people who inject drugs and participate in a methadone substitution treatment program.
Krekulová L; Vavrinčíková L
Epidemiol Mikrobiol Imunol; 2021; 70(1):18-25. PubMed ID: 33853334
[TBL] [Abstract][Full Text] [Related]
10. Acute searching and early diagnosis of HCV infected persons.
Husa Ml P; Husa P
Vnitr Lek; 2021; 67(8):455-458. PubMed ID: 35459364
[TBL] [Abstract][Full Text] [Related]
11. Can hepatitis C virus infection be eradicated in people who inject drugs?
Grebely J; Dore GJ
Antiviral Res; 2014 Apr; 104():62-72. PubMed ID: 24468275
[TBL] [Abstract][Full Text] [Related]
12. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
[TBL] [Abstract][Full Text] [Related]
13. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.
Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J
Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194
[TBL] [Abstract][Full Text] [Related]
14. Belgian experience with direct acting antivirals in people who inject drugs.
Bielen R; Moreno C; Van Vlierberghe H; Bourgeois S; Mulkay JP; Vanwolleghem T; Verlinden W; Brixko C; Decaestecker J; De Galocsy C; Janssens F; Cool M; Van Overbeke L; Van Steenkiste C; D'heygere F; Cools W; Nevens F; Robaeys G
Drug Alcohol Depend; 2017 Aug; 177():214-220. PubMed ID: 28618285
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
[TBL] [Abstract][Full Text] [Related]
16. From Prioritization to Universal Treatment: Successes and Challenges of Hepatitis C Virus Elimination in Italy.
Kondili LA; Craxì L; Nava F; Babudieri S; D'Ambrosio R; Marcellusi A; Mennini FS; Valle S; Russo P; Olimpieri PP; Andreoni M; Aghemo A
J Infect Dis; 2023 Sep; 228(Suppl 3):S211-S220. PubMed ID: 37703346
[TBL] [Abstract][Full Text] [Related]
17. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes.
Ruta S; Cernescu C
World J Gastroenterol; 2015 Oct; 21(38):10811-23. PubMed ID: 26478672
[TBL] [Abstract][Full Text] [Related]
18. Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs.
Sulkowski MS; Martinez A; Tyson GL; Scholz K; Franco RA; Kohli A; Julius SF; Deming P; Fink SA; Lynch K; Roytman M; Stainbrook TR; Turner MD; Viera-Briggs M; Ramers CB
J Viral Hepat; 2024 Jun; 31(6):342-356. PubMed ID: 38433561
[TBL] [Abstract][Full Text] [Related]
19. Integrating hepatitis C and addiction care for people who inject drugs in the era of direct-acting antiviral therapy.
Bird K; Socías ME; Ti L
Int J Drug Policy; 2018 Sep; 59():1-2. PubMed ID: 29960218
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C treatment uptake among patients who have received methadone substitution treatment in the Republic of Georgia.
Stvilia K; Vephkvadze N; Gamkrelidze A; Khonelidze I; Getia V; Tsereteli M; Gvinjilia L; Kuchuloria T
Public Health; 2021 Jun; 195():42-50. PubMed ID: 34051674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
